Aeterna Zentaris (AEZS) 3.61 $AEZS
Aeterna Zentaris Reports Second Quarter 2016 Financial and Operating Results
BusinessWire - Tue Aug 09, 3:30PM CDT
--All $ amounts are in US Dollars
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Expands Promotion of APIFINY(R) into Florida
BusinessWire - Mon Aug 08, 7:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
today announced that it is expanding its promotion of APIFINY(R), the only cancer-specific, non-PSA blood test available to assess the risk for the presence of prostate cancer, into the important Florida market pursuant to its exclusive promotional agreement with Armune BioScience, Inc. ("Armune", the owner of the product. The expansion into Florida follows Armune's receipt of a clinical laboratory license from the State of Florida.
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris and Rafa Laboratories Sign Exclusive License Agreement for Zoptrex(TM) in Israel
BusinessWire - Mon Aug 01, 7:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZ) (the "Company" and Rafa Laboratories, Ltd. ("Rafa" today announced the signing of an exclusive license agreement for the Company's lead anti-cancer compound, Zoptrex(TM) (zoptarelin doxorubicin), for the initial indication of endometrial cancer, for Israel and the Palestinian Territories (the "Territory". Zoptrex(TM), a novel synthetic peptide carrier linked to doxorubicin, is currently in a fully-enrolled Phase 3 clinical trial in endometrial cancer. The Company expects to complete the Phase 3 clinical trial in the third quarter of 2016 and, if the results of the trial warrant doing so, to file a new drug application for Zoptrex(TM) in the first half of 2017.
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Announces IND Submission by Sinopharm A-Think
BusinessWire - Tue Jun 14, 4:00PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced that its licensee, Sinopharm A-Think Pharmaceuticals Co., Ltd. ("Sinopharm A-Think", which is affiliated with the largest state-owned pharmaceutical company in the People's Republic of China, today submitted an Investigational New Drug application ("IND" for Zoptrex(TM) to the Chinese State Food and Drug Administration ("CFDA", remaining on track to commence its clinical program during the first half of 2017.
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Reconfirms Commitment to LHRH-receptor Targeting Zoptrex(TM) During 2016 ASCO Annual Meeting
BusinessWire - Mon Jun 06, 4:00PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company" today reconfirmed its commitment to LHRH-receptor targeted therapy and its expectation that the pivotal, phase 3 trial for Zoptrex(TM) (zoptarelin doxorubicin) in women with advanced, recurrent endometrial cancer, is expected to be completed in the third quarter of 2016. During the 2016 Annual Meeting of the American Society of Clinical Oncologists ("ASCO", the Company also discussed its plans to develop Zoptrex(TM) for additional indications, based upon achieving a positive outcome in the current clinical program.
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Elects Ms. Carolyn Egbert as Independent Chair of the Board
BusinessWire - Mon May 23, 7:15PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company", a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health, today announced the separation of the positions of Chairman of the Board and President and Chief Executive Officer. Ms. Carolyn Egbert has been elected Chair of the Board, a non-executive position, by the Company's Board of Directors, and the position of Lead Director was eliminated. David A. Dodd, who has served as Chairman, President and Chief Executive Officer since 2014, will continue to serve as President and Chief Executive Officer of the Company and as a director. Mr. Juergen Ernst, the former Lead Director, will remain as a director of the Company.
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Announces Election of Directors at 2016 Shareholders' Meeting
BusinessWire - Tue May 10, 3:00PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company", a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health, today announced the results of the vote on directors held at its 2016 annual meeting of shareholders held earlier today on May 10, 2016. Each of the director nominees proposed by management for election was elected as director, without a vote by ballot being conducted. The Company received proxies with regard to voting on the six directors nominated for election as set forth in the table below:
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris reports 1Q loss
Automated Insights - Mon May 09, 5:26PM CDT
MONTREAL (AP) _ Aeterna Zentaris Inc. (AEZS) on Monday reported a loss of $3.7 million in its first quarter.
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Acquires Exclusive U.S. Promotional Rights for APIFINY(R) Prostate Cancer Blood Test
BusinessWire - Wed Apr 27, 3:06PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced that, effective as of June 1, 2016, it has acquired the exclusive right to promote APIFINY(R), the only cancer specific, non-PSA blood test to assess the risk for the presence of prostate cancer, throughout the entire United States pursuant to a new co-marketing agreement with Armune BioScience, Inc.
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris to Announce First Quarter 2016 Financial and Operating Results on May 9, 2016
BusinessWire - Tue Apr 26, 7:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" will announce its first quarter 2016 financial and operating results after market close on Monday, May 9, 2016. The Company will host a conference call and webcast to discuss these results on Tuesday, May 10, 2016 at 8:30 a.m. Eastern Time.
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Announces At the Market Issuance Program
BusinessWire - Fri Apr 01, 4:05PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company" announced today that it has entered into an At Market Issuance ("ATM" Sales Agreement, dated April 1, 2016, with H.C. Wainwright & Co., LLC (the "Sales Agent", under which the Company may, at its discretion, from time to time during the term of the ATM Sales Agreement, sell up to a maximum of 3,000,000 of its common shares through ATM issuances on the NASDAQ Stock Market, up to an aggregate amount of approximately $10 million. The Sales Agent will act as sales agent for any sales made under this new ATM program. The common shares will be sold at market prices prevailing at the time of the sale of the common shares and, as a result, sale prices may vary.
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2015 Financial and Operating Results
BusinessWire - Tue Mar 29, 4:00PM CDT
--All amounts are in US Dollars
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris to Participate in 18th Annual BIO CEO & Investor Conference Seeking Partnering Opportunities
BusinessWire - Mon Feb 01, 4:33PM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced that Chairman, President and Chief Executive Officer David A. Dodd will participate in the 18th Annual BIO CEO & Investor Conference, on February 8 & 9,2016 in New York City. Mr. Dodd will update participants on the status of the Company's two Phase 3 clinical trials and will continue the Company's efforts to secure additional partners for the development of Zoptrex(TM), which if approved by the FDA, would be the first systemic therapy for the treatment of advanced and recurrent endometrial cancer, and for Macrilen(TM), which if approved by the FDA, would be the first orally administered drug indicated for the evaluation of adult growth hormone deficiency ("AGHD". The Company continues to actively seek opportunities to in-license and acquire products for US commercialization, consistent with its goal of becoming a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of its product portfolio.
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Announces Appointments to Board of Directors
BusinessWire - Fri Jan 29, 7:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced the appointment of Michael Cardiff and Ken Newport to its Board of Directors, effective immediately, for a term to expire at the Company's upcoming 2016 annual meeting of shareholders, whereupon it is anticipated that each of Messrs. Cardiff and Newport will stand for election as director candidates to be nominated by management.
AEZ.TO: 4.73 (-0.02), IBM: 158.88 (-0.52), AEZS: 3.61 (-0.02)
Aeterna Zentaris Files International Patent Application for Novel Method of Manufacturing Zoptrex(TM)
BusinessWire - Tue Jan 26, 7:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced that it has filed an international patent application as well as national patent applications in selected countries including the US, China, Taiwan, Japan and India. These applications seek to protect the novel method of manufacturing Zoptrex(TM) (zoptarelin doxorubicin), and were filed in addition to a European patent application filed last year. The Company decided to file patent applications in additional territories after the European Patent Office issued a search report for the European patent application that the Company considers to be favorable.
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris reports on-market purchases of USD90,000 common stock by executive management
M2 - Tue Jan 26, 3:26AM CST
Biopharmaceutical company Aeterna Zentaris (NASDAQ:AEZS) (TSX:AEZ) said on Monday that certain members of its executive management team have made on-market purchases of an aggregate of 29,535 of its common shares last week at then market prices, representing a total investment of approximately USD90,000.
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Announces Additional Market Purchases of Common Shares by Executive Management
BusinessWire - Mon Jan 25, 7:30AM CST
Aeterna Zentaris Inc. (NASDAQ:AEZS; TSX:AEZ) (the "Company" today disclosed that it was advised by certain members of its executive management team that such executives made on-market purchases of an aggregate of 29,535 of the Company's Common Shares last week at then market prices, representing a total investment by such executives of approximately $90,000. David A. Dodd, Chairman, President and Chief Executive Officer, purchased 16,300 Common Shares for a total investment of approximately $50,000; Jude Dinges, Senior Vice President and Chief Commercial Officer, purchased 6,500 Common Shares for a total investment of approximately $20,000; and Philip A. Theodore, Senior Vice President, Chief Administrative Officer and General Counsel, purchased 6,735 Common Shares for a total investment of approximately $20,000.
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
4 Small Cap NASDAQ/NYSE Stocks That Are Trading with Heavy Volume Today
ACCESSWIRE - Tue Jan 19, 11:52AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / The Stock Expert is issuing a report on four stocks to watch. CMRX, AEZS, TMST and GBSN have been attracting the attention of major investors today. Continue reading to find out why.
GBSN: 0.20 (unch), TMST: 9.85 (-0.20), CMRX: 4.81 (+0.23), AEZS: 3.61 (-0.02)
Aeterna Zentaris Concludes Successful Meeting of Clinical Investigators for Confirmatory Phase 3 Trial of Macrilen(TM)
BusinessWire - Tue Jan 19, 7:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company" announced today that it concluded a successful meeting of the clinical investigators for the confirmatory Phase 3 trial of Macrilen(TM) (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency ("AGHD". As a result, the Company is confident that it will complete the confirmatory trial by year-end 2016.
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Reports Second Quarter 2016 Financial and Operating Results
BusinessWire - Tue Aug 09, 3:30PM CDT
--All $ amounts are in US Dollars
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Expands Promotion of APIFINY(R) into Florida
BusinessWire - Mon Aug 08, 7:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
today announced that it is expanding its promotion of APIFINY(R), the only cancer-specific, non-PSA blood test available to assess the risk for the presence of prostate cancer, into the important Florida market pursuant to its exclusive promotional agreement with Armune BioScience, Inc. ("Armune", the owner of the product. The expansion into Florida follows Armune's receipt of a clinical laboratory license from the State of Florida. AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris and Rafa Laboratories Sign Exclusive License Agreement for Zoptrex(TM) in Israel
BusinessWire - Mon Aug 01, 7:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZ) (the "Company"
and Rafa Laboratories, Ltd. ("Rafa" today announced the signing of an exclusive license agreement for the Company's lead anti-cancer compound, Zoptrex(TM) (zoptarelin doxorubicin), for the initial indication of endometrial cancer, for Israel and the Palestinian Territories (the "Territory". Zoptrex(TM), a novel synthetic peptide carrier linked to doxorubicin, is currently in a fully-enrolled Phase 3 clinical trial in endometrial cancer. The Company expects to complete the Phase 3 clinical trial in the third quarter of 2016 and, if the results of the trial warrant doing so, to file a new drug application for Zoptrex(TM) in the first half of 2017. AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Announces IND Submission by Sinopharm A-Think
BusinessWire - Tue Jun 14, 4:00PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
today announced that its licensee, Sinopharm A-Think Pharmaceuticals Co., Ltd. ("Sinopharm A-Think", which is affiliated with the largest state-owned pharmaceutical company in the People's Republic of China, today submitted an Investigational New Drug application ("IND" for Zoptrex(TM) to the Chinese State Food and Drug Administration ("CFDA", remaining on track to commence its clinical program during the first half of 2017. AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Reconfirms Commitment to LHRH-receptor Targeting Zoptrex(TM) During 2016 ASCO Annual Meeting
BusinessWire - Mon Jun 06, 4:00PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"
today reconfirmed its commitment to LHRH-receptor targeted therapy and its expectation that the pivotal, phase 3 trial for Zoptrex(TM) (zoptarelin doxorubicin) in women with advanced, recurrent endometrial cancer, is expected to be completed in the third quarter of 2016. During the 2016 Annual Meeting of the American Society of Clinical Oncologists ("ASCO", the Company also discussed its plans to develop Zoptrex(TM) for additional indications, based upon achieving a positive outcome in the current clinical program. AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Elects Ms. Carolyn Egbert as Independent Chair of the Board
BusinessWire - Mon May 23, 7:15PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
, a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health, today announced the separation of the positions of Chairman of the Board and President and Chief Executive Officer. Ms. Carolyn Egbert has been elected Chair of the Board, a non-executive position, by the Company's Board of Directors, and the position of Lead Director was eliminated. David A. Dodd, who has served as Chairman, President and Chief Executive Officer since 2014, will continue to serve as President and Chief Executive Officer of the Company and as a director. Mr. Juergen Ernst, the former Lead Director, will remain as a director of the Company. AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Announces Election of Directors at 2016 Shareholders' Meeting
BusinessWire - Tue May 10, 3:00PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
, a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health, today announced the results of the vote on directors held at its 2016 annual meeting of shareholders held earlier today on May 10, 2016. Each of the director nominees proposed by management for election was elected as director, without a vote by ballot being conducted. The Company received proxies with regard to voting on the six directors nominated for election as set forth in the table below: AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris reports 1Q loss
Automated Insights - Mon May 09, 5:26PM CDT
MONTREAL (AP) _ Aeterna Zentaris Inc. (AEZS) on Monday reported a loss of $3.7 million in its first quarter.
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Acquires Exclusive U.S. Promotional Rights for APIFINY(R) Prostate Cancer Blood Test
BusinessWire - Wed Apr 27, 3:06PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"
today announced that, effective as of June 1, 2016, it has acquired the exclusive right to promote APIFINY(R), the only cancer specific, non-PSA blood test to assess the risk for the presence of prostate cancer, throughout the entire United States pursuant to a new co-marketing agreement with Armune BioScience, Inc. AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris to Announce First Quarter 2016 Financial and Operating Results on May 9, 2016
BusinessWire - Tue Apr 26, 7:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
will announce its first quarter 2016 financial and operating results after market close on Monday, May 9, 2016. The Company will host a conference call and webcast to discuss these results on Tuesday, May 10, 2016 at 8:30 a.m. Eastern Time. AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Announces At the Market Issuance Program
BusinessWire - Fri Apr 01, 4:05PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"
announced today that it has entered into an At Market Issuance ("ATM" Sales Agreement, dated April 1, 2016, with H.C. Wainwright & Co., LLC (the "Sales Agent", under which the Company may, at its discretion, from time to time during the term of the ATM Sales Agreement, sell up to a maximum of 3,000,000 of its common shares through ATM issuances on the NASDAQ Stock Market, up to an aggregate amount of approximately $10 million. The Sales Agent will act as sales agent for any sales made under this new ATM program. The common shares will be sold at market prices prevailing at the time of the sale of the common shares and, as a result, sale prices may vary. AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2015 Financial and Operating Results
BusinessWire - Tue Mar 29, 4:00PM CDT
--All amounts are in US Dollars
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris to Participate in 18th Annual BIO CEO & Investor Conference Seeking Partnering Opportunities
BusinessWire - Mon Feb 01, 4:33PM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"
today announced that Chairman, President and Chief Executive Officer David A. Dodd will participate in the 18th Annual BIO CEO & Investor Conference, on February 8 & 9,2016 in New York City. Mr. Dodd will update participants on the status of the Company's two Phase 3 clinical trials and will continue the Company's efforts to secure additional partners for the development of Zoptrex(TM), which if approved by the FDA, would be the first systemic therapy for the treatment of advanced and recurrent endometrial cancer, and for Macrilen(TM), which if approved by the FDA, would be the first orally administered drug indicated for the evaluation of adult growth hormone deficiency ("AGHD". The Company continues to actively seek opportunities to in-license and acquire products for US commercialization, consistent with its goal of becoming a growth-oriented specialty biopharmaceutical company by pursuing successful development and commercialization of its product portfolio. AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Announces Appointments to Board of Directors
BusinessWire - Fri Jan 29, 7:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"
today announced the appointment of Michael Cardiff and Ken Newport to its Board of Directors, effective immediately, for a term to expire at the Company's upcoming 2016 annual meeting of shareholders, whereupon it is anticipated that each of Messrs. Cardiff and Newport will stand for election as director candidates to be nominated by management. AEZ.TO: 4.73 (-0.02), IBM: 158.88 (-0.52), AEZS: 3.61 (-0.02)
Aeterna Zentaris Files International Patent Application for Novel Method of Manufacturing Zoptrex(TM)
BusinessWire - Tue Jan 26, 7:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"
today announced that it has filed an international patent application as well as national patent applications in selected countries including the US, China, Taiwan, Japan and India. These applications seek to protect the novel method of manufacturing Zoptrex(TM) (zoptarelin doxorubicin), and were filed in addition to a European patent application filed last year. The Company decided to file patent applications in additional territories after the European Patent Office issued a search report for the European patent application that the Company considers to be favorable. AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris reports on-market purchases of USD90,000 common stock by executive management
M2 - Tue Jan 26, 3:26AM CST
Biopharmaceutical company Aeterna Zentaris (NASDAQ:AEZS) (TSX:AEZ) said on Monday that certain members of its executive management team have made on-market purchases of an aggregate of 29,535 of its common shares last week at then market prices, representing a total investment of approximately USD90,000.
AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
Aeterna Zentaris Announces Additional Market Purchases of Common Shares by Executive Management
BusinessWire - Mon Jan 25, 7:30AM CST
Aeterna Zentaris Inc. (NASDAQ:AEZS; TSX:AEZ) (the "Company"
today disclosed that it was advised by certain members of its executive management team that such executives made on-market purchases of an aggregate of 29,535 of the Company's Common Shares last week at then market prices, representing a total investment by such executives of approximately $90,000. David A. Dodd, Chairman, President and Chief Executive Officer, purchased 16,300 Common Shares for a total investment of approximately $50,000; Jude Dinges, Senior Vice President and Chief Commercial Officer, purchased 6,500 Common Shares for a total investment of approximately $20,000; and Philip A. Theodore, Senior Vice President, Chief Administrative Officer and General Counsel, purchased 6,735 Common Shares for a total investment of approximately $20,000. AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
4 Small Cap NASDAQ/NYSE Stocks That Are Trading with Heavy Volume Today
ACCESSWIRE - Tue Jan 19, 11:52AM CST
NEW YORK, NY / ACCESSWIRE / January 19, 2016 / The Stock Expert is issuing a report on four stocks to watch. CMRX, AEZS, TMST and GBSN have been attracting the attention of major investors today. Continue reading to find out why.
GBSN: 0.20 (unch), TMST: 9.85 (-0.20), CMRX: 4.81 (+0.23), AEZS: 3.61 (-0.02)
Aeterna Zentaris Concludes Successful Meeting of Clinical Investigators for Confirmatory Phase 3 Trial of Macrilen(TM)
BusinessWire - Tue Jan 19, 7:30AM CST
Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"
announced today that it concluded a successful meeting of the clinical investigators for the confirmatory Phase 3 trial of Macrilen(TM) (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency ("AGHD". As a result, the Company is confident that it will complete the confirmatory trial by year-end 2016. AEZ.TO: 4.73 (-0.02), AEZS: 3.61 (-0.02)
